Compound amino acid (19) propyl glutamine dipeptide injection was approved for drug marketing by the

    On August 10, 2022, our company's product compound amino acid (19) propyl glutamine dipeptide injection, specification: 250ml: 25g (amino acid/propyl glutamine dipeptide), was approved by the State Drug Administration, the approval number is: Sinomedical approval number H20220018.
    Compound amino acid (19) propyl glutamine dipeptide injection (20AA) is a new compound preparation approved according to the original Class 1.5 of chemical drugs. After years of clinical research and persistence, it has finally been approved by the State Drug Administration (NMPA).
    This product is composed of 19 kinds of amino acids and alanyl glutamine, can provide relatively complete 20 kinds of amino acids, including cysteine, taurine, tyrosine, glutamine, the amino acid ratio is close to the whole egg amino acid ratio, the formula is reasonable, the prescription does not contain antioxidants. It has patents of "new compound amino acid composition" and "one amino acid composition". It is an amino acid injection that has completed clinical trials in China. The clinical research team leader is Peking Union Medical College Hospital.
    This product has a wide range of clinical use (can be used in the general practice), and the indication is to provide parenteral nutrition and supplement amino acids for adult patients when enteral nutrition is not feasible, insufficient or contraindicated. This product contains alanyl glutamine and is suitable for adult trauma patients.
    This product can not only meet the needs of the body to synthesize protein, help to improve the nitrogen balance and protein nutrition, but also protect the gastrointestinal function, improve the body's antioxidant capacity, enhance the body's immune function, prevent infection, promote wound healing, and maintain the body's normal physiological function.